DH — Definitive Healthcare Corp.

Summary of Definitive Healthcare's Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total revenue for Q3 2025 was $60 million, a 4% decline year-over-year, but at the high end of guidance.
• Adjusted EBITDA reached $18.9 million, representing a 32% margin, exceeding guidance by $2 million.
• Unlevered free cash flow for the trailing 12 months was approximately $51 million, with $17.9 million generated in Q3 alone.
• Adjusted net income was $9.7 million, translating to $0.07 per share.
• Total customer count remained stable at about 2,400, with enterprise customers increasing to 520.

2. Strategic Updates and Business Highlights:

• The company is focused on four strategic pillars: differentiated data, seamless integrations, customer success, and innovation.
• Improvements in renewal rates were noted, although the company remains cautious about the durability of this trend.
• New data sources are being integrated to enhance data quality, with a new claims data source expected to improve offerings.
• Partnerships with agencies and digital platforms (e.g., LiveRamp) are expanding, enhancing the company's digital marketing capabilities.
• The company reported successful case studies where clients have significantly increased their commitments based on the effectiveness of Definitive's data.

3. Forward Guidance and Outlook:

• For Q4 2025, revenue is expected to be between $59 million and $60 million, reflecting a 4% to 5% decline year-over-year.
• Full-year revenue guidance has been raised to $239 million to $240 million, a 5% decline year-over-year.
• Adjusted EBITDA for the full year is projected at $68 million to $69 million, with a margin of 28% to 29%.
• The company anticipates continued pressure on net dollar retention (NRR) for 2025, with expectations of modest declines.

4. Bad News, Challenges, or Points of Concern:

• Total revenue has declined year-over-year, indicating potential challenges in growth.
• The company faces ongoing pressures in the life sciences sector, impacting upsell opportunities and contributing to downsell pressures.
• The upcoming December and January renewal periods are critical, with over 30% of annual renewals occurring during this time, raising concerns about potential churn.
• Competitive pressures remain, particularly in the life sciences space, which could impact future growth.

5. Notable Q&A Insights:

• Management expressed confidence in the quality of their data and the effectiveness of their go-to-market strategies, which are showing early positive impacts on customer retention and new logo acquisition.
• There is a cautious optimism regarding the upcoming renewal period, with management focused on maximizing outcomes despite external economic pressures.
• The integration of new claims data sources is seen as crucial for regaining competitive positioning and enhancing product offerings.
• The company is not currently planning significant pricing changes but will continue to implement normal pricing increases in agreements.
• Management emphasized the importance of executing on strategic pillars to return to revenue growth, with a focus on improving customer relationships and retention.